Effects of NAD Supplementation on Sleep Quality

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the impact of nicotinamide adenine dinucleotide (NAD) supplementation, specifically in the form of nicotinamide riboside (NR), on sleep quality in healthy adults compared to a placebo. The research aims to determine whether NAD supplementation can enhance sleep by restoring the brain's neurophysiological capacity to rest. Participants aged 40 to 60 will receive either NAD or a placebo, and their sleep will be monitored using polysomnography and actigraphy to assess any differences in sleep quality and quantity. The study focuses on the potential benefits of NAD in improving mitochondrial function and reducing oxidative stress, which are crucial for healthy sleep.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant must be 40 to 60 years of age inclusive, at the time of signing the informed consent.
* Male or female.
* Participants who are healthy as determined by medical evaluation including medical history and physical examination.
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the study protocol.
* Self-reported normal sleep patterns, assessed by Pittsburgh sleep quality index (PSQI; cutoff ≤ 5).
* No current use of sleep medications or supplements.
* Able to wear polysomnographic equipment and actigraphy during nighttime.

Exclusion Criteria:

* History of sleep disorders (e.g. insomnia, sleep apnea).
* Abnormal findings on PSG, such as sleep related breathing disorders (apnea-hypopnea index (AHI) ≥ 5), sleep related movement disorders (periodic limb movement index (PLMI) ≥ 15, and parasomnias (like REM sleep behavior disorder (RBD)).
* Chronic use of alcohol, tobacco, or medications affecting sleep.
* Significant psychiatric or medical conditions (including neurological, heart, lung, or sleep disorders/diseases).
* Travelled \>1 time zone and night work \<1 month before study, or during the study.
* Extreme chronotype according to the Composite Morningness Questionnaire (evening type; \<22 and morning type \>44).
* Pregnancy.
* Breastfeeding.
* Supplements resulting in \> 20 mg daily of nicotinamide riboside, nicotinamide mononucleotide (NMN), niacin (vitamin B3, nicotinic acid amide or other vitamin B3 analogues) less than 3 months prior to randomization.
* Participation in other clinical trials last 3 months.
* Deemed ineligible by lead principal investigator.

Where it's running

• Haukeland University Hospital
  Bergen, Norway Recruiting

Study contacts

• Principal investigator: Katarina Lundervold, MD — University of Bergen
• Study coordinator: Charalampos Tzoulis, PhD
• Email: charalampos.tzoulis@helse-bergen.no
• Phone: 55975061

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nicotinamide Riboside by Mouth for Early Alzheimer’s Disease (2-Year Trial)

  This study tests whether taking nicotinamide riboside every day for 24 months can slow progression in adults with early Alzheimer’s disease.

  Recruiting Phase 2 Haukeland University Hospital · Bergen and 1 other locations · NCT07741071

• Effect of a Liberal Fasting Regime on Preoperative Gastric Volume Measured by Ultrasound

  This study tests whether letting adults drink small amounts of clear liquid up to when they’re called for surgery (sip-to-send) is not worse than the standard fasting for keeping the stomach empty before general anesthesia.

  Recruiting Haukeland University Hospital · Bergen, Vestland · NCT07656649

• eCardiacRehab: a home-based, patient-centered cardiac rehab program

  This trial tests a hybrid home-based cardiac rehabilitation program to see if it reduces cardiovascular deaths and ED visits while improving quality of life for adults with CAD after PCI, compared with usual care.

  Recruiting Haukeland University Hospital · Bergen · NCT07590635

• D-SPARK: D‑Serine to modify Parkinson's progression

  This trial will test whether taking D‑serine can slow Parkinson's progression in people diagnosed within five years.

  Recruiting at 3 sites Phase 2 Haukeland University Hospital · Arendal, Agder and 10 other locations · NCT07312110

• Big Five daily actions program adapted for Norway

  This trial will test whether a brief Norwegian program encouraging five daily actions helps people in Norway with mild-to-moderate anxiety or depression compared with a gratitude activity or no treatment.

  Recruiting Haukeland University Hospital · Bergen, Vestland and 1 other locations · NCT07151573

• Behavioral therapy plus GLP-1 medicines for binge eating and weight in people with obesity

  This project will try adding GLP-1 medications to a lifestyle program with CBT-E to see if they reduce binge eating and help adults with obesity lose weight and cope better.

  Recruiting Haukeland University Hospital · Bergen, Vestland · NCT07042672

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.